# UPLIZNA® (inebilizumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/inebilizumab

> The FDA approved UPLIZNA® (inebilizumab), sponsored by AMGEN INC (AMGN), on Dec 2025 for generalized myasthenia gravis.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | UPLIZNA® (inebilizumab) |
| Codes |  |
| Sponsor | AMGEN INC (AMGN) https://sec-api.dev/companies/amgn/catalysts |
| Indications | [immunoglobulin g4-related disease](https://sec-api.dev/indications/immunoglobulin-g4-related-disease), [generalized myasthenia gravis](https://sec-api.dev/indications/generalized-myasthenia-gravis), [Neuromyelitis Optica Spectrum Disorder](https://sec-api.dev/indications/neuromyelitis-optica-spectrum-disorder) |
| Modality | antibody |
| FDA designations | orphan, priority review |

## Timeline

### Jun 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3. Indication: Immunoglobulin G4-related disease.
- First seen 2025-02-14, last confirmed 2025-02-14.
- SEC Form 10-K (accession 0000318154-25-000010): "In June 2024, we announced positive top-line results from our Phase 3 registrational trial evaluating UPLIZNA for the treatment of Immunoglobulin G4-related disease (IgG4-RD)." https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/amgn-20241231.htm

### Apr 2025: FDA approval

- Status: completed, approved. Date confidence: month. Indication: Immunoglobulin G4-related disease.
- First seen 2025-05-02, last confirmed 2026-02-13.
- SEC Form 10-K (accession 0000318154-26-000010): "In April 2025, we announced the FDA approved UPLIZNA for the treatment of Immunoglobulin G4-related disease (IgG4-RD) in adult patients." https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm
- SEC Form 10-Q (accession 0000318154-25-000020): "In April 2025, we announced the FDA approved UPLIZNA for the treatment of Immunoglobulin G4-related disease (IgG4-RD) in adult patients." https://www.sec.gov/Archives/edgar/data/318154/000031815425000020/amgn-20250331.htm

### Dec 2025: FDA approval

- Status: completed, approved. Date confidence: month. Indication: generalized myasthenia gravis.
- First seen 2026-02-13, last confirmed 2026-02-13.
- SEC Form 10-K (accession 0000318154-26-000010): "In December 2025, we announced the FDA approved UPLIZNA for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) and anti-muscle specific tyrosine kinase (MuSK) antibody positive." https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm

### 2026: trial start

- Status: scheduled. Date confidence: year. Stage: 3.
- First seen 2026-02-03, last confirmed 2026-02-03.
- Press release filed with the SEC (EX-99) (accession 0000318154-26-000003): "•The Company expects to initiate Phase 3 studies of UPLIZNA in patients with autoimmune hepatitis and in patients with chronic inflammatory demyelinating polyneuropathy in 2026." https://www.sec.gov/Archives/edgar/data/318154/000031815426000003/amgn-20251231earningsrelea.htm

### Apr to Jul 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Neuromyelitis Optica Spectrum Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05549258 (Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-13 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT05549258

### April 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Neuromyelitis Optica Spectrum Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05549258 (Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-13 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT05549258

### Mar to Jun 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Generalized Myasthenia Gravis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06987539 (A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-03-13 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT06987539

### March 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Generalized Myasthenia Gravis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06987539 (A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-03-13 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT06987539

## Same indication

- [Obexelimab](https://sec-api.dev/pdufa/obexelimab) (ZBIO)
- [Ultomiris® (ravulizumab)](https://sec-api.dev/pdufa/ravulizumab) (AZN)

Calendar months: [April 2027](https://sec-api.dev/fda-calendar/2027-04)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/inebilizumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "UPLIZNA® (inebilizumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/inebilizumab

```bibtex
@misc{secapidev_pdufa_inebilizumab_20261116,
  title        = {UPLIZNA® (inebilizumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/inebilizumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_inebilizumab_20261116","title":"UPLIZNA® (inebilizumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/inebilizumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
